HomeSGMO • NASDAQ
add
Sangamo Therapeutics Inc
Previous close
$1.22
Day range
$1.12 - $1.25
Year range
$0.30 - $3.18
Market cap
243.07M USD
Avg Volume
9.10M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | 49.41M | 425.77% |
Operating expense | 8.65M | -37.86% |
Net income | 10.67M | 110.25% |
Net profit margin | 21.60 | 101.95% |
Earnings per share | — | — |
EBITDA | 14.25M | 125.39% |
Effective tax rate | 0.82% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 39.20M | -70.33% |
Total assets | 111.26M | -49.36% |
Total liabilities | 72.13M | -14.92% |
Total equity | 39.13M | — |
Shares outstanding | 208.65M | — |
Price to book | 6.39 | — |
Return on assets | 31.90% | — |
Return on capital | 54.46% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | 10.67M | 110.25% |
Cash from operations | 11.76M | 124.86% |
Cash from investing | 233.00K | -99.38% |
Cash from financing | -203.00K | -103.00% |
Net change in cash | 12.92M | 225.19% |
Free cash flow | 10.99M | 134.43% |
About
Sangamo Therapeutics, Inc. is an American biotechnology company based in Brisbane, California. It applies cell and gene therapy to combat haemophilia and other genetic diseases. Wikipedia
CEO
Founded
1995
Headquarters
Website
Employees
405
